

Cell-specific retroviral vectors with antibody domains suitable for cell-specific transduction of selected mammal cell types

Patent number: DE19752854
Publication date: 1999-07-01
Inventor: CICHUTEK KLAUS DR (DE); ENGELSTAEDTER MARTIN (DE)
Applicant: BUNDESREPUBLIK DEUTSCHLAND LET (DE)
Classification:
- **international:** C07K16/28; C12N15/86; C12N15/867; A61K48/00; C07K16/18; C12N15/86; C12N15/867; A61K48/00; (IPC1-7): C12N15/79; A61K48/00; C12N15/86
- **european:** C07K16/28; C07K16/28S; C12N15/86C8; C12N15/867
Application number: DE19971052854 19971128
Priority number(s): DE19971052854 19971128

Also published as:



WO9928489 (A3)
WO9928489 (A3)
WO9928489 (A2)
EP1034292 (A3)
EP1034292 (A3)

more >>

[Report a data error here](#)

Abstract of DE19752854

Cell-specific retroviral vectors with antibody domains suitable for cell-specific transduction of selected mammal cell types, are new. A method to produce cell-specific retroviral vectors, consists essentially of the following steps: (a) immunization of a mammal with one or more cell populations; (b) isolation of RNA from the immunized mammal, especially the B cell RNA; (c) production of a cDNA strand of the variable region of the heavy and light chains of the immunoglobulins isolated from the RNA by RT-PCR with primers for the respective immunoglobulin chains, where the primer nucleic acid sequences are essentially for an oligopeptide linker; (d) ligation of the cDNA strand to scFv-cDNA; (e) ligation of the scFv cDNA in a phagemid vector and transformation of a host bacterium with the vector; (f) isolation of phage, by selection of phage that bind to the cell population used in step (a); (g) cleavage of the scFv coding DNA fragments from the cell-specific phage and ligation into a psi-negative retroviral Env-expression vector; (h) transformation of a Env-ScFv expression vector to be maintain in a packaging cell; and (i) isolation of a packaging cell with the retroviral vectors. Independent claims are also included for the following: (1) a retroviral vector, produced by a method as above; and (2) a retroviral packaging cell for housing retroviral vectors as above.

Data supplied from the esp@cenet database - Worldwide